MultiOmic Health
MultiOmic Health is an AI-enabled drug discovery company dedicated to developing novel therapeutics and diagnostics for serious complications of metabolic dysfunction, which is the world's largest healthcare burden. Using a unique combination of deep longitudinal patient datasets, AI-enabled data science, and experimental biology, they identify patient subpopulations with distinct molecular disease drivers to originate and pursue their own therapeutic R&D programs, including drug discovery pipelines and companion diagnostics. Their mission is to transform patient outcomes through precision medicine for metabolic syndrome-related conditions. The company is actively collaborating with partners such as Mesh Bio to leverage AI for developing precision medicines and diagnostics for chronic metabolic diseases.
Industries
Nr. of Employees
small (1-50)
Services
Precision biomarker and endotype discovery
Analysis of bespoke longitudinal cohorts to identify patient endotypes and develop predictive biomarker models for disease trajectory and treatment response.
AI-enabled target discovery and therapeutic concept generation
Using integrated multi-omics, machine learning and systems-biology modelling to identify and prioritise novel drug targets and therapeutic concepts, including repositioning and combination strategies.
Wet-lab validation and preclinical support
Targeted in vitro and ex vivo experiments to validate computational hypotheses and support selection of preclinical development candidates and IND-enabling studies.
Diagnostic assay development and laboratory deployment
Design and commissioning of laboratory services to implement stratifying biomarker assays as laboratory-developed tests or IVDs to support clinical trials and clinical decision-making.
Platform deployment and partnership models
Deployment of an integrated Patient-to-Data and Data-to-Therapeutics platform through value-sharing partnerships, licensing arrangements and co-funded discovery programs.
Drug repositioning and combination therapy identification
Analysis and modelling to identify existing NMEs or drug combinations that may be effective in specific patient endotypes for repurposing efforts.
Precision biomarker and endotype discovery
Analysis of bespoke longitudinal cohorts to identify patient endotypes and develop predictive biomarker models for disease trajectory and treatment response.
AI-enabled target discovery and therapeutic concept generation
Using integrated multi-omics, machine learning and systems-biology modelling to identify and prioritise novel drug targets and therapeutic concepts, including repositioning and combination strategies.
Wet-lab validation and preclinical support
Targeted in vitro and ex vivo experiments to validate computational hypotheses and support selection of preclinical development candidates and IND-enabling studies.
Diagnostic assay development and laboratory deployment
Design and commissioning of laboratory services to implement stratifying biomarker assays as laboratory-developed tests or IVDs to support clinical trials and clinical decision-making.
Platform deployment and partnership models
Deployment of an integrated Patient-to-Data and Data-to-Therapeutics platform through value-sharing partnerships, licensing arrangements and co-funded discovery programs.
Drug repositioning and combination therapy identification
Analysis and modelling to identify existing NMEs or drug combinations that may be effective in specific patient endotypes for repurposing efforts.
Expertise Areas
- Multi-omics data generation and integration
- Longitudinal cohort curation and de-identified clinical data management
- AI/ML-driven biomarker discovery and patient stratification
- Systems biology modelling and simulation
Key Technologies
- Next-generation sequencing
- Epigenomic profiling
- Transcriptomics
- Mass-spectrometry proteomics